Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S.
Identifieur interne : 001771 ( Ncbi/Merge ); précédent : 001770; suivant : 001772Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S.
Auteurs : Sara Akerström [Suède] ; Ali Mirazimi ; Yee-Joo TanSource :
- Antiviral research [ 0166-3542 ] ; 2007.
Descripteurs français
- KwdFr :
- ARN messager (génétique), Animaux, Cellules Vero, Petit ARN interférent (génétique), Protéines de la matrice virale (biosynthèse), Protéines de la matrice virale (génétique), Protéines virales (biosynthèse), Protéines virales (génétique), Réplication virale (génétique), Spécificité du substrat, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (génétique), Syndrome respiratoire aigu sévère (virologie), Technique d'immunofluorescence (), Virus du SRAS (génétique), Virus du SRAS (physiologie).
- MESH :
- biosynthèse : Protéines de la matrice virale, Protéines virales.
- génétique : ARN messager, Petit ARN interférent, Protéines de la matrice virale, Protéines virales, Réplication virale, Syndrome respiratoire aigu sévère, Virus du SRAS.
- physiologie : Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Cellules Vero, Spécificité du substrat, Syndrome respiratoire aigu sévère, Technique d'immunofluorescence.
English descriptors
- KwdEn :
- Animals, Chlorocebus aethiops, Fluorescent Antibody Technique (methods), RNA, Messenger (genetics), RNA, Small Interfering (genetics), SARS Virus (genetics), SARS Virus (physiology), Severe Acute Respiratory Syndrome (genetics), Severe Acute Respiratory Syndrome (therapy), Severe Acute Respiratory Syndrome (virology), Substrate Specificity, Vero Cells, Viral Matrix Proteins (biosynthesis), Viral Matrix Proteins (genetics), Viral Proteins (biosynthesis), Viral Proteins (genetics), Virus Replication (genetics).
- MESH :
- chemical , biosynthesis : Viral Matrix Proteins, Viral Proteins.
- chemical , genetics : RNA, Messenger, RNA, Small Interfering, Viral Matrix Proteins, Viral Proteins.
- genetics : SARS Virus, Severe Acute Respiratory Syndrome, Virus Replication.
- methods : Fluorescent Antibody Technique.
- physiology : SARS Virus.
- therapy : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Chlorocebus aethiops, Substrate Specificity, Vero Cells.
Abstract
The severe acute respiratory syndrome coronavirus (SARS CoV) genome has 14 potential open reading frames (ORFs). The first ORF is translated from the full-length genomic mRNA while the remaining ORFs are translated from eight subgeomic RNAs (sgRNAs). In this study, we designed small interference RNAs (siRNAs) targeting sgRNA 2, 3 and 7 and tested their efficiency and specificity in silencing the protein translated from the targeted sgRNA. Our results demonstrated that siRNA 7 could inhibit sgRNA 7, which showed 19/19 nucleotides (nt) matching, and sgRNA 8, which showed 18/19 nt matching; but, it did not inhibit the full-length genomic mRNA which showed 17/19 nt matching. Overall, each of the siRNAs can inhibit the targeted sgRNA without affecting the full-length genomic mRNA or the other sgRNAs that showed mismatch of two or more nt. Thus, siRNA could be designed so as to knockdown the expression of viral protein(s) from a targeted sgRNA during viral infection, thereby allowing the contribution of individual viral proteins to viral infection to be delineated. When Vero E6 cells expressing siRNA 2, 3 or 7 were infected with SARS-CoV, a significant reduction in the yield of progeny virus was observed. Indirect immunofluorescence assays showed that in the infected cells expressing each of the siRNAs, there was aspecific silencing of S, 3a and 7a, respectively, but the expression of nucleocapsid protein was not affected. Thus, our data suggests that the accessory proteins, i.e. 3a and 7a, could play an important role during the replication cycle of the SARS-CoV.
DOI: 10.1016/j.antiviral.2006.10.008
PubMed: 17112601
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001F83
- to stream PubMed, to step Curation: 001F83
- to stream PubMed, to step Checkpoint: 001D76
Links to Exploration step
pubmed:17112601Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S.</title>
<author><name sortKey="Akerstrom, Sara" sort="Akerstrom, Sara" uniqKey="Akerstrom S" first="Sara" last="Akerström">Sara Akerström</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Microbiological Preparedness, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Center for Microbiological Preparedness, Swedish Institute for Infectious Disease Control, SE-171 82 Solna</wicri:regionArea>
<wicri:noRegion>SE-171 82 Solna</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mirazimi, Ali" sort="Mirazimi, Ali" uniqKey="Mirazimi A" first="Ali" last="Mirazimi">Ali Mirazimi</name>
</author>
<author><name sortKey="Tan, Yee Joo" sort="Tan, Yee Joo" uniqKey="Tan Y" first="Yee-Joo" last="Tan">Yee-Joo Tan</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17112601</idno>
<idno type="pmid">17112601</idno>
<idno type="doi">10.1016/j.antiviral.2006.10.008</idno>
<idno type="wicri:Area/PubMed/Corpus">001F83</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F83</idno>
<idno type="wicri:Area/PubMed/Curation">001F83</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F83</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001D76</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001D76</idno>
<idno type="wicri:Area/Ncbi/Merge">001771</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S.</title>
<author><name sortKey="Akerstrom, Sara" sort="Akerstrom, Sara" uniqKey="Akerstrom S" first="Sara" last="Akerström">Sara Akerström</name>
<affiliation wicri:level="1"><nlm:affiliation>Center for Microbiological Preparedness, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Center for Microbiological Preparedness, Swedish Institute for Infectious Disease Control, SE-171 82 Solna</wicri:regionArea>
<wicri:noRegion>SE-171 82 Solna</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mirazimi, Ali" sort="Mirazimi, Ali" uniqKey="Mirazimi A" first="Ali" last="Mirazimi">Ali Mirazimi</name>
</author>
<author><name sortKey="Tan, Yee Joo" sort="Tan, Yee Joo" uniqKey="Tan Y" first="Yee-Joo" last="Tan">Yee-Joo Tan</name>
</author>
</analytic>
<series><title level="j">Antiviral research</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Fluorescent Antibody Technique (methods)</term>
<term>RNA, Messenger (genetics)</term>
<term>RNA, Small Interfering (genetics)</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (physiology)</term>
<term>Severe Acute Respiratory Syndrome (genetics)</term>
<term>Severe Acute Respiratory Syndrome (therapy)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Substrate Specificity</term>
<term>Vero Cells</term>
<term>Viral Matrix Proteins (biosynthesis)</term>
<term>Viral Matrix Proteins (genetics)</term>
<term>Viral Proteins (biosynthesis)</term>
<term>Viral Proteins (genetics)</term>
<term>Virus Replication (genetics)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN messager (génétique)</term>
<term>Animaux</term>
<term>Cellules Vero</term>
<term>Petit ARN interférent (génétique)</term>
<term>Protéines de la matrice virale (biosynthèse)</term>
<term>Protéines de la matrice virale (génétique)</term>
<term>Protéines virales (biosynthèse)</term>
<term>Protéines virales (génétique)</term>
<term>Réplication virale (génétique)</term>
<term>Spécificité du substrat</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (génétique)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Technique d'immunofluorescence ()</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Viral Matrix Proteins</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Messenger</term>
<term>RNA, Small Interfering</term>
<term>Viral Matrix Proteins</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Protéines de la matrice virale</term>
<term>Protéines virales</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN messager</term>
<term>Petit ARN interférent</term>
<term>Protéines de la matrice virale</term>
<term>Protéines virales</term>
<term>Réplication virale</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Fluorescent Antibody Technique</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Substrate Specificity</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Cellules Vero</term>
<term>Spécificité du substrat</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Technique d'immunofluorescence</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome coronavirus (SARS CoV) genome has 14 potential open reading frames (ORFs). The first ORF is translated from the full-length genomic mRNA while the remaining ORFs are translated from eight subgeomic RNAs (sgRNAs). In this study, we designed small interference RNAs (siRNAs) targeting sgRNA 2, 3 and 7 and tested their efficiency and specificity in silencing the protein translated from the targeted sgRNA. Our results demonstrated that siRNA 7 could inhibit sgRNA 7, which showed 19/19 nucleotides (nt) matching, and sgRNA 8, which showed 18/19 nt matching; but, it did not inhibit the full-length genomic mRNA which showed 17/19 nt matching. Overall, each of the siRNAs can inhibit the targeted sgRNA without affecting the full-length genomic mRNA or the other sgRNAs that showed mismatch of two or more nt. Thus, siRNA could be designed so as to knockdown the expression of viral protein(s) from a targeted sgRNA during viral infection, thereby allowing the contribution of individual viral proteins to viral infection to be delineated. When Vero E6 cells expressing siRNA 2, 3 or 7 were infected with SARS-CoV, a significant reduction in the yield of progeny virus was observed. Indirect immunofluorescence assays showed that in the infected cells expressing each of the siRNAs, there was aspecific silencing of S, 3a and 7a, respectively, but the expression of nucleocapsid protein was not affected. Thus, our data suggests that the accessory proteins, i.e. 3a and 7a, could play an important role during the replication cycle of the SARS-CoV.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17112601</PMID>
<DateCompleted><Year>2007</Year>
<Month>07</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0166-3542</ISSN>
<JournalIssue CitedMedium="Print"><Volume>73</Volume>
<Issue>3</Issue>
<PubDate><Year>2007</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Antiviral research</Title>
<ISOAbbreviation>Antiviral Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S.</ArticleTitle>
<Pagination><MedlinePgn>219-27</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The severe acute respiratory syndrome coronavirus (SARS CoV) genome has 14 potential open reading frames (ORFs). The first ORF is translated from the full-length genomic mRNA while the remaining ORFs are translated from eight subgeomic RNAs (sgRNAs). In this study, we designed small interference RNAs (siRNAs) targeting sgRNA 2, 3 and 7 and tested their efficiency and specificity in silencing the protein translated from the targeted sgRNA. Our results demonstrated that siRNA 7 could inhibit sgRNA 7, which showed 19/19 nucleotides (nt) matching, and sgRNA 8, which showed 18/19 nt matching; but, it did not inhibit the full-length genomic mRNA which showed 17/19 nt matching. Overall, each of the siRNAs can inhibit the targeted sgRNA without affecting the full-length genomic mRNA or the other sgRNAs that showed mismatch of two or more nt. Thus, siRNA could be designed so as to knockdown the expression of viral protein(s) from a targeted sgRNA during viral infection, thereby allowing the contribution of individual viral proteins to viral infection to be delineated. When Vero E6 cells expressing siRNA 2, 3 or 7 were infected with SARS-CoV, a significant reduction in the yield of progeny virus was observed. Indirect immunofluorescence assays showed that in the infected cells expressing each of the siRNAs, there was aspecific silencing of S, 3a and 7a, respectively, but the expression of nucleocapsid protein was not affected. Thus, our data suggests that the accessory proteins, i.e. 3a and 7a, could play an important role during the replication cycle of the SARS-CoV.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akerström</LastName>
<ForeName>Sara</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Center for Microbiological Preparedness, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mirazimi</LastName>
<ForeName>Ali</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>Yee-Joo</ForeName>
<Initials>YJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2006</Year>
<Month>11</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Antiviral Res</MedlineTA>
<NlmUniqueID>8109699</NlmUniqueID>
<ISSNLinking>0166-3542</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C488151">sars7a protein, SARS virus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year>
<Month>02</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2006</Year>
<Month>10</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2006</Year>
<Month>10</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>11</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>7</Month>
<Day>21</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>11</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">17112601</ArticleId>
<ArticleId IdType="pii">S0166-3542(06)00317-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.antiviral.2006.10.008</ArticleId>
<ArticleId IdType="pmc">PMC7114101</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>EMBO J. 2001 Dec 3;20(23):6877-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11726523</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2005 Dec;114(1-2):70-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16046244</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>JAMA. 2003 Nov 26;290(20):2665-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14645307</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2004 May 7;565(1-3):111-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15135062</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Med. 2005 Sep;11(9):944-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16116432</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2003 Sep;84(Pt 9):2305-2315</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12917450</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6047-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11972060</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2003 Oct 10;315(1):80-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592761</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2005 Jan;65(1):45-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15652970</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Clin Microbiol. 2004 Jul;42(7):3196-206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15243082</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2006 Nov;72(2):78-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16820226</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chin Med J (Engl). 2005 Feb 20;118(4):267-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15740663</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Dec;79(23):14909-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16282490</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Feb;79(3):1966-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15650225</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 2004 Feb 27;560(1-3):141-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14988013</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2004 Jul 1;324(2):251-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15207612</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Ther. 2004 Jun;9(3):365-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15259899</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Mol Biol. 2003 Aug 29;331(5):991-1004</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12927536</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Structure. 2005 Jan;13(1):75-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15642263</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2004 Jun 20;324(1):84-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15183056</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2005 Jul;86(Pt 7):1921-1930</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15958670</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Diagn Lab Immunol. 2004 Mar;11(2):362-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15013989</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12995-3000</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14569023</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Mol Biol. 2004 Jul 30;341(1):271-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15312778</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Jul;78(13):6723-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15194747</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Ther. 2005;10(4):527-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16038478</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Gene Ther. 2005 May;12(9):751-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15772689</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Jul;78(14):7523-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220426</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Jul;78(14):7311-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15220404</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(20):11429-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15452268</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virol J. 2005 Aug 17;2:66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16107218</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Mod Pathol. 2005 Nov;18(11):1432-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15920543</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Suède</li>
</country>
</list>
<tree><noCountry><name sortKey="Mirazimi, Ali" sort="Mirazimi, Ali" uniqKey="Mirazimi A" first="Ali" last="Mirazimi">Ali Mirazimi</name>
<name sortKey="Tan, Yee Joo" sort="Tan, Yee Joo" uniqKey="Tan Y" first="Yee-Joo" last="Tan">Yee-Joo Tan</name>
</noCountry>
<country name="Suède"><noRegion><name sortKey="Akerstrom, Sara" sort="Akerstrom, Sara" uniqKey="Akerstrom S" first="Sara" last="Akerström">Sara Akerström</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001771 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001771 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:17112601 |texte= Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:17112601" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |